We advised the placing agent on the transaction

Davis Polk advised the sole placing agent on the placing of 69,256,000 shares in Ascletis Pharma Inc. for an aggregate consideration of HK$843.5 million.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Ascletis is listed on the Hong Kong Stock Exchange.

The Davis Polk team included partner Xuelin (Steve) Wang, counsel Vanessa Chan and associate Marco Cheng. All members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post